Haemonetics Corp. 10-Q Summary: Quarter Ended September 30, 2000
Business Context and Reporting Period
Haemonetics Corporation designs, manufactures, and markets automated blood processing systems, including blood bank, surgical, and plasma products. This report covers the three and six months ended September 30, 2000 (Fiscal Year 2001). The period is significantly impacted by the acquisition of Transfusion Technologies Corporation on September 18, 2000.
Key Financial Metrics
| Metric | 3 Months Ended Sept 30, 2000 | 6 Months Ended Sept 30, 2000 |
|---|---|---|
| Net Revenues | $70.6 million | $140.3 million |
| Gross Profit | $33.4 million (47.3% margin) | $66.8 million (47.6% margin) |
| Operating Income (Loss) | $(14.4) million | $(6.5) million |
| Net Income (Loss) | $(15.1) million | $(8.9) million |
| Diluted EPS | $(0.602) | $(0.353) |
| Cash from Operations | N/A (Quarterly not provided) | $24.7 million |
| Ending Cash Balance | $38.6 million | $38.6 million |
| Total Debt (Current + Long-term) | $58.9 million | $58.9 million |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 3.5% year-over-year for the quarter and 2.1% for the six-month period. Growth was driven by surgical and blood bank disposables, offset by a decline in plasma sales and equipment revenues.
- Profitability Decline: The company reported a net loss of $15.1 million for the quarter compared to a net income of $5.7 million in the prior year quarter. This reversal is primarily due to non-recurring acquisition charges.
- Acquisition Charges: The quarter included $18.6 million in In-Process Research and Development (IPR&D) expenses and $4.2 million in other unusual charges related to the Transfusion Technologies acquisition. These charges totaled $22.8 million for the quarter.
- Working Capital: Cash and short-term investments decreased from $61.3 million to $38.6 million, largely due to the $26.6 million cash outlay for the Transfusion acquisition.
Guidance, Outlook, and Risks
- Acquisition Integration: Management expects approximately $1.5 million in additional cash costs for restructuring and integrating Transfusion Technologies over the next six months, to be financed by internal cash flows.
- Product Outlook: The company anticipates continued growth in surgical and blood bank markets due to volume increases and new product rollouts (e.g., red cell disposables). Plasma sales remain under pressure due to market factors and donor availability.
- Foreign Exchange: Over two-thirds of revenues are generated outside the U.S. The company uses forward contracts to hedge firm sales commitments. A 10% strengthening of the U.S. dollar would result in a $10.4 million unrealized gain on these contracts, while a 10% weakening would result in an $11.9 million unrealized loss.
- Regulatory & Market Risks: Risks include regulatory changes, market acceptance of new technologies, and the impact of the Euro currency conversion on European operations.
Investor Verification Checklist
- Acquisition Valuation: Verify the assumptions used to value the $18.6 million IPR&D charge, specifically the projected cash flows and discount rates for the Chairside Separator and Red Cell Collector projects.
- Plasma Segment Trends: Investigate the specific market factors driving the 4.7% decline in plasma sales to determine if this is a temporary or structural issue.
- Debt Covenants: Review the impact of the recent debt reduction ($15 million paid down) and the new $10 million mortgage commitment on liquidity and covenant compliance.
- Pro Forma Adjustments: Analyze the pro forma financial data provided to understand the underlying operating performance excluding the one-time acquisition charges.